Disclosed herein are methods for the reduction of inter-patient variability of a drug, such as in one or more parameters including half-life (t
1/2
), maximum plasma concentration (C
max
), time at maximal plasma concentration (T
max
), area under the time-versus-concentration curve (AUC). Also provided are methods of reducing side effects associated with drugs.
US9533952B2
申请人:——
公开号:US9533952B2
公开(公告)日:2017-01-03
[EN] N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS<br/>[FR] DÉRIVÉS DE N-PROP-2-YNYL-CARBOXAMIDE ET LEUR UTILISATION À TITRE D'ANTAGONISTES DE TRPA1
申请人:ORION CORP
公开号:WO2014053694A1
公开(公告)日:2014-04-10
Compounds of formula I, wherein A, B, X, Z and R1-R6, are as defined in the claims, exhibit TRPA 1 activity and are thus useful as TRPA1 modulators.
N-PROP-2-YNYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS
申请人:ORION CORPORATION
公开号:US20150376130A1
公开(公告)日:2015-12-31
Compounds of formula I, wherein A, B, X, Z and R
1
-R
6
, are as defined in the claims, exhibit TRPA 1 activity and are thus useful as TRPA1 modulators.